Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Biological Markers in Retinal Vasculitis
Identification of Biological Markers in Retinal Vasculitis
Status: Enrolling
Updated:  9/26/2015
National Eye Institute (NEI)
mi
from
Bethesda, MD
Biological Markers in Retinal Vasculitis
Identification of Biological Markers in Retinal Vasculitis
Status: Enrolling
Updated: 9/26/2015
National Eye Institute (NEI)
mi
from
Bethesda, MD
Click here to add this to my saved trials
Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy
Investigation of the Effect of Dietary Docosahexaenoic Acid (DHA) Supplementation on Macular Function in Subjects With Autosomal Dominant Stargardt-Like and Autosomal Recessive Stargardt Macular Dystrophy
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy
Investigation of the Effect of Dietary Docosahexaenoic Acid (DHA) Supplementation on Macular Function in Subjects With Autosomal Dominant Stargardt-Like and Autosomal Recessive Stargardt Macular Dystrophy
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa
Pilot Study on the Effect of Vitamin A Supplementation on Cone Function in Retinitis Pigmentosa
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa
Pilot Study on the Effect of Vitamin A Supplementation on Cone Function in Retinitis Pigmentosa
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Pilot Study of Laser Photocoagulation Therapy for Diabetic Macular Edema
A Pilot Study of Laser Photocoagulation for Diabetic Macular Edema
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Pilot Study of Laser Photocoagulation Therapy for Diabetic Macular Edema
A Pilot Study of Laser Photocoagulation for Diabetic Macular Edema
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Pilot Study of Laser Photocoagulation Therapy for Diabetic Macular Edema
A Pilot Study of Laser Photocoagulation for Diabetic Macular Edema
Status: Enrolling
Updated:  9/26/2015
Diabetic Retinopathy Clinical Research Network
mi
from
Bethesda, MD
Pilot Study of Laser Photocoagulation Therapy for Diabetic Macular Edema
A Pilot Study of Laser Photocoagulation for Diabetic Macular Edema
Status: Enrolling
Updated: 9/26/2015
Diabetic Retinopathy Clinical Research Network
mi
from
Bethesda, MD
Click here to add this to my saved trials
Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis
Daclizumab for Active, Non-infectious, Sight-threatening Uveitis: A Phase II Pilot Study
Status: Enrolling
Updated:  9/26/2015
National Eye Institute (NEI)
mi
from
Bethesda, MD
Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis
Daclizumab for Active, Non-infectious, Sight-threatening Uveitis: A Phase II Pilot Study
Status: Enrolling
Updated: 9/26/2015
National Eye Institute (NEI)
mi
from
Bethesda, MD
Click here to add this to my saved trials
Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders
Pilot Study of Intravitreal Injection of Triamcinolone Acetonide Formulation for Retinal Vascular Disorders
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders
Pilot Study of Intravitreal Injection of Triamcinolone Acetonide Formulation for Retinal Vascular Disorders
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Digital Photography to Evaluate Dry Eye
Digital Image Based Determination of Ocular Surface Vital Dye Staining
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Digital Photography to Evaluate Dry Eye
Digital Image Based Determination of Ocular Surface Vital Dye Staining
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Infliximab to Treat Non-Infectious Scleritis
Pilot Study of the Evaluation of Infliximab in the Treatment of Non-Infectious Scleritis
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Infliximab to Treat Non-Infectious Scleritis
Pilot Study of the Evaluation of Infliximab in the Treatment of Non-Infectious Scleritis
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Evaluation and Treatment of Pediatric, Developmental, and Genetic Eye Diseases
Evaluation and Treatment of Pediatric, Developmental and Genetic Eye Diseases
Status: Enrolling
Updated:  9/26/2015
Rocky Mountain Lions Eye Institute
mi
from
Denver, CO
Evaluation and Treatment of Pediatric, Developmental, and Genetic Eye Diseases
Evaluation and Treatment of Pediatric, Developmental and Genetic Eye Diseases
Status: Enrolling
Updated: 9/26/2015
Rocky Mountain Lions Eye Institute
mi
from
Denver, CO
Click here to add this to my saved trials
Evaluation and Treatment of Pediatric, Developmental, and Genetic Eye Diseases
Evaluation and Treatment of Pediatric, Developmental and Genetic Eye Diseases
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Evaluation and Treatment of Pediatric, Developmental, and Genetic Eye Diseases
Evaluation and Treatment of Pediatric, Developmental and Genetic Eye Diseases
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Daclizumab and Sirolimus to Treat Uveitis
Combination Daclizumab/Sirolimus Therapy For the Induction of Immune Tolerance in Non-Infectious Intermediate and Posterior Uveitis
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Daclizumab and Sirolimus to Treat Uveitis
Combination Daclizumab/Sirolimus Therapy For the Induction of Immune Tolerance in Non-Infectious Intermediate and Posterior Uveitis
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Screening for Research Subjects With Anterior Segment Diseases
Screening Study for the Evaluation and Diagnosis of Potential Research Subjects With Anterior Segment Disease
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Screening for Research Subjects With Anterior Segment Diseases
Screening Study for the Evaluation and Diagnosis of Potential Research Subjects With Anterior Segment Disease
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Immune Indicators of Uveitis
Use of Immune Cell Markers, Cytokines, Transcription Factors and Surface CD Markers as Markers of Ocular Inflammatory Activity
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Immune Indicators of Uveitis
Use of Immune Cell Markers, Cytokines, Transcription Factors and Surface CD Markers as Markers of Ocular Inflammatory Activity
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders
Phase I Study of Intravitreal Injections Versus Anterior Sub-Tenon Injections of Triamcinolone Acetonide Formulation for Macular Edema in Retinal Disorders
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders
Phase I Study of Intravitreal Injections Versus Anterior Sub-Tenon Injections of Triamcinolone Acetonide Formulation for Macular Edema in Retinal Disorders
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Treatment of Diabetic Macular Edema: Triamcinolone Injections Vs. Laser Photocoagulation
A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema
Status: Enrolling
Updated:  9/26/2015
National Eye Institute (NEI)
mi
from
Bethesda, MD
Treatment of Diabetic Macular Edema: Triamcinolone Injections Vs. Laser Photocoagulation
A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema
Status: Enrolling
Updated: 9/26/2015
National Eye Institute (NEI)
mi
from
Bethesda, MD
Click here to add this to my saved trials
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
Systemic Immunosupressive Therapy for Eye Diseases (SITE) Cohort Study
Status: Enrolling
Updated:  9/26/2015
Johns Hopkins University
mi
from
Baltimore, MD
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
Systemic Immunosupressive Therapy for Eye Diseases (SITE) Cohort Study
Status: Enrolling
Updated: 9/26/2015
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
Systemic Immunosupressive Therapy for Eye Diseases (SITE) Cohort Study
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
Systemic Immunosupressive Therapy for Eye Diseases (SITE) Cohort Study
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
Systemic Immunosupressive Therapy for Eye Diseases (SITE) Cohort Study
Status: Enrolling
Updated:  9/26/2015
Massachusetts Eye & Ear Infirmary
mi
from
Boston, MA
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
Systemic Immunosupressive Therapy for Eye Diseases (SITE) Cohort Study
Status: Enrolling
Updated: 9/26/2015
Massachusetts Eye & Ear Infirmary
mi
from
Boston, MA
Click here to add this to my saved trials
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
Systemic Immunosupressive Therapy for Eye Diseases (SITE) Cohort Study
Status: Enrolling
Updated:  9/26/2015
Oregon Health and Sciences University
mi
from
Portland, OR
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
Systemic Immunosupressive Therapy for Eye Diseases (SITE) Cohort Study
Status: Enrolling
Updated: 9/26/2015
Oregon Health and Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials
Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60
Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60
Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Correlation of Gene Abnormalities and Clinical Manifestations of Aniridia
Phenotype-Genotype Correlation in Aniridia
Status: Enrolling
Updated:  9/26/2015
University of Chicago
mi
from
Chicago, IL
Correlation of Gene Abnormalities and Clinical Manifestations of Aniridia
Phenotype-Genotype Correlation in Aniridia
Status: Enrolling
Updated: 9/26/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Correlation of Gene Abnormalities and Clinical Manifestations of Aniridia
Phenotype-Genotype Correlation in Aniridia
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Correlation of Gene Abnormalities and Clinical Manifestations of Aniridia
Phenotype-Genotype Correlation in Aniridia
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Correlation of Gene Abnormalities and Clinical Manifestations of Aniridia
Phenotype-Genotype Correlation in Aniridia
Status: Enrolling
Updated:  9/26/2015
University of Cincinnati
mi
from
Cincinnati, OH
Correlation of Gene Abnormalities and Clinical Manifestations of Aniridia
Phenotype-Genotype Correlation in Aniridia
Status: Enrolling
Updated: 9/26/2015
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Differences in Genes and Proteins in Active and Controlled Uveitis
Analysis of Differential Gene Expression Profiles in Patients With Defined Ocular Inflammatory Diseases Using CDNA Microarrays and Proteomics
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Differences in Genes and Proteins in Active and Controlled Uveitis
Analysis of Differential Gene Expression Profiles in Patients With Defined Ocular Inflammatory Diseases Using CDNA Microarrays and Proteomics
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Genetic Study of Age-Related Macular Degeneration
A Case Control Study of Age-Related Macular Degeneration (AMD) Examining Gene Expression Patterns in Circulating Monocytes From Peripheral Blood Samples
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Genetic Study of Age-Related Macular Degeneration
A Case Control Study of Age-Related Macular Degeneration (AMD) Examining Gene Expression Patterns in Circulating Monocytes From Peripheral Blood Samples
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Metabolic Mapping to Measure Retinal Metabolism
A Novel Non-Invasive In Vivo Imaging System to Measure Retinal Metabolism
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Metabolic Mapping to Measure Retinal Metabolism
A Novel Non-Invasive In Vivo Imaging System to Measure Retinal Metabolism
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Potential Research Participants for Future Studies of Inherited Eye Diseases
Evaluation and Treatment Protocol for Potential Research Participants With Inherited Ophthalmic Diseases
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Potential Research Participants for Future Studies of Inherited Eye Diseases
Evaluation and Treatment Protocol for Potential Research Participants With Inherited Ophthalmic Diseases
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Validation of Computerized Vision-Targeted Quality-of-Life Questionnaires
Pilot Validation Study of Computer Administration of Vision Targeted Quality of Life Instruments
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Validation of Computerized Vision-Targeted Quality-of-Life Questionnaires
Pilot Validation Study of Computer Administration of Vision Targeted Quality of Life Instruments
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Subconjunctival Sirolimus for the Treatment of Autoimmune Active Anterior Uveiti
Subconjunctival Sirolimus for the Treatment of Autoimmune Active Anterior Uveitis
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Subconjunctival Sirolimus for the Treatment of Autoimmune Active Anterior Uveiti
Subconjunctival Sirolimus for the Treatment of Autoimmune Active Anterior Uveitis
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma
The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma
The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
RESEARCH PROTOCOL: Glaucoma Treatment Adherence and Persistence
An Assessment of the Impact of Motivational Interviewing Via Glaucoma Educator on Glaucoma Treatment Adherence and Persistence
Status: Enrolling
Updated:  9/30/2015
Lions Eye Institute, UC Denver
mi
from
Aurora, CO
RESEARCH PROTOCOL: Glaucoma Treatment Adherence and Persistence
An Assessment of the Impact of Motivational Interviewing Via Glaucoma Educator on Glaucoma Treatment Adherence and Persistence
Status: Enrolling
Updated: 9/30/2015
Lions Eye Institute, UC Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
RESEARCH PROTOCOL: Glaucoma Treatment Adherence and Persistence
An Assessment of the Impact of Motivational Interviewing Via Glaucoma Educator on Glaucoma Treatment Adherence and Persistence
Status: Enrolling
Updated:  9/30/2015
Devers Eye Institute
mi
from
Portland, OR
RESEARCH PROTOCOL: Glaucoma Treatment Adherence and Persistence
An Assessment of the Impact of Motivational Interviewing Via Glaucoma Educator on Glaucoma Treatment Adherence and Persistence
Status: Enrolling
Updated: 9/30/2015
Devers Eye Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Effectiveness of Wavefront-Guided LASIK Corrections of Myopic Refractive Errors
A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided LASIK Correction of Myopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4IR™ Excimer Laser
Status: Enrolling
Updated:  9/30/2015
Contact Abbott Medical Optics for locations
mi
from
Milpitas, CA
Safety and Effectiveness of Wavefront-Guided LASIK Corrections of Myopic Refractive Errors
A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided LASIK Correction of Myopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4IR™ Excimer Laser
Status: Enrolling
Updated: 9/30/2015
Contact Abbott Medical Optics for locations
mi
from
Milpitas, CA
Click here to add this to my saved trials
Comparative Evaluation of Corneal Staining With Balafilcon A Lenses and Two Multi-Purpose Solutions
Status: Enrolling
Updated:  9/30/2015
Abbott Medical Optics Inc.
mi
from
Santa Ana, CA
Comparative Evaluation of Corneal Staining With Balafilcon A Lenses and Two Multi-Purpose Solutions
Status: Enrolling
Updated: 9/30/2015
Abbott Medical Optics Inc.
mi
from
Santa Ana, CA
Click here to add this to my saved trials
A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration
A Phase 1/2, Open-Label, Dose-Escalation, Single Center, Clinical Study of MTP-131 (Ocuvia™) Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration.
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Boston, MA
A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration
A Phase 1/2, Open-Label, Dose-Escalation, Single Center, Clinical Study of MTP-131 (Ocuvia™) Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration.
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea
Subconjunctival Aflibercept Injection for Corneal Neovascularization
Status: Enrolling
Updated:  10/5/2015
John A. Moran Eye Center
mi
from
Salt Lake City, UT
Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea
Subconjunctival Aflibercept Injection for Corneal Neovascularization
Status: Enrolling
Updated: 10/5/2015
John A. Moran Eye Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Status: Enrolling
Updated:  10/5/2015
Novartis Investigative Site
mi
from
Beverly Hills, CA
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Status: Enrolling
Updated: 10/5/2015
Novartis Investigative Site
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Status: Enrolling
Updated:  10/5/2015
Novartis Investigative Site
mi
from
Cambridge, MA
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Status: Enrolling
Updated: 10/5/2015
Novartis Investigative Site
mi
from
Cambridge, MA
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Status: Enrolling
Updated:  10/5/2015
Novartis Investigative Site
mi
from
Slingerlands, NY
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Status: Enrolling
Updated: 10/5/2015
Novartis Investigative Site
mi
from
Slingerlands, NY
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Status: Enrolling
Updated:  10/5/2015
Novartis Investigative Site
mi
from
Arlington, TX
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Status: Enrolling
Updated: 10/5/2015
Novartis Investigative Site
mi
from
Arlington, TX
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Status: Enrolling
Updated:  10/5/2015
Novartis Investigative Site
mi
from
Houston, TX
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Status: Enrolling
Updated: 10/5/2015
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Status: Enrolling
Updated:  10/5/2015
Novartis Investigative Site
mi
from
London,
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Status: Enrolling
Updated: 10/5/2015
Novartis Investigative Site
mi
from
London,
Click here to add this to my saved trials
Maestro Agreement and Precision Study II
Topcon 3D OCT-1 Maestro Agreement and Precision Study II
Status: Enrolling
Updated:  10/7/2015
Western University of Health Sciences
mi
from
Pomona, CA
Maestro Agreement and Precision Study II
Topcon 3D OCT-1 Maestro Agreement and Precision Study II
Status: Enrolling
Updated: 10/7/2015
Western University of Health Sciences
mi
from
Pomona, CA
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 24 Week Multi-center, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis.
Status: Enrolling
Updated:  10/8/2015
Emory University
mi
from
Atlanta, GA
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 24 Week Multi-center, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis.
Status: Enrolling
Updated: 10/8/2015
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 24 Week Multi-center, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis.
Status: Enrolling
Updated:  10/8/2015
Massachusets Eye Research and Surgery Institution (MERSI)
mi
from
Cambridge, MA
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 24 Week Multi-center, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis.
Status: Enrolling
Updated: 10/8/2015
Massachusets Eye Research and Surgery Institution (MERSI)
mi
from
Cambridge, MA
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 24 Week Multi-center, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis.
Status: Enrolling
Updated:  10/8/2015
Charlotte Eye, Ear, Nose, and Throat Associates
mi
from
Belmont, NC
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 24 Week Multi-center, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis.
Status: Enrolling
Updated: 10/8/2015
Charlotte Eye, Ear, Nose, and Throat Associates
mi
from
Belmont, NC
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 24 Week Multi-center, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis.
Status: Enrolling
Updated:  10/8/2015
Houston Eye Associates
mi
from
Houston, TX
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 24 Week Multi-center, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis.
Status: Enrolling
Updated: 10/8/2015
Houston Eye Associates
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 24 Week Multi-center, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis.
Status: Enrolling
Updated:  10/8/2015
Sall Research Medical Center, Inc.
mi
from
Artesia, CA
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 24 Week Multi-center, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis.
Status: Enrolling
Updated: 10/8/2015
Sall Research Medical Center, Inc.
mi
from
Artesia, CA
Click here to add this to my saved trials
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 24 Week Multi-center, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis.
Status: Enrolling
Updated:  10/8/2015
Novartis Investigative Site
mi
from
Artesia, CA
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 24 Week Multi-center, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis.
Status: Enrolling
Updated: 10/8/2015
Novartis Investigative Site
mi
from
Artesia, CA
Click here to add this to my saved trials